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SkinFibrosis or scarring of diverse organs and tissues is considered as a pathologic consequence of a chronically
altered wound healing response which is tightly linked to inﬂammation and angiogenesis. The recruitment
of immune cells, local proliferation of ﬁbroblasts and the consecutive accumulation of extracellular matrix
proteins are common pathophysiological hallmarks of tissue ﬁbrosis, irrespective of the organ involved.
Chemokines, a family of chemotactic cytokines, appear to be central mediators of the initiation as well as pro-
gression of these biological processes. Traditionally chemokines have only been considered to play a critical
role in orchestrating the inﬂux of immune cells to sites of tissue injury. However, within the last years, further
aspects of chemokine biology including ﬁbroblast activation and angiogenesis have been deciphered in tissue
ﬁbrosis of many different organs. Interestingly, certain chemokines appear to mediate common effects in
liver, kidney, lung, and skin of various animal models, while others mediate tissue speciﬁc effects. These as-
pects have to be kept in mind when extrapolating data of animal studies to early human trials. Nevertheless,
the further understanding of chemokine effects in tissue ﬁbrosis might be an attractive approach for identi-
fying novel therapeutic targets in chronic organ damage associated with high morbidity and mortality. This
article is part of a Special Issue entitled: Fibrosis: Translation of basic research to human disease.
© 2012 Published by Elsevier B.V.1. General aspects of tissue ﬁbrogenesis
Under physiological conditions wound healing is a dynamic pro-
cess involving four sequential phases: hemostasis, inﬂammation,
proliferation and ﬁnally tissue remodeling. The proliferative phase
is characterized by angiogenesis, expansion of ﬁbroblasts and
re-epithelialization after resolution of the acute tissue injury mecha-
nism [1]. In contrast to acute damage, during chronic tissue injury of
different causes (e.g. autoimmune, toxic, viral etc.) the balance be-
tween extracellular matrix (ECM) synthesis and its degradation is
skewed towards an accumulation of scar tissue [2,3]. Although such
process of tissue repair and remodeling is effective in creating a func-
tional barrier within or between organs, aberrant wound healing and
continued exposure to chronic injury can result in tissue scarring (ﬁbro-
sis) and ultimately in loss of function of the affected organ. This chronic
pathogenic process involves the recruitment and activation of ﬁbro-
blasts. Upon activation by resident cells, ﬁbroblasts promote increased
tissue remodeling associated with enhanced expression of matrix
metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases
(TIMPs),which aremainly stimulated by TGF-β. Other cytokines such ass: Translation of basic research
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sevier B.V.platelet derived growth factor (PDGF), epidermal growth factor (EGF)
and angiotensin II support themitogenic activity of ﬁbrogenic cells. Fur-
thermore, recruited inﬂammatory cells lead to persistent ﬁbrogenic re-
sponses by expression of soluble factors and oxidative stress-related
molecules [4]. This appears to be functionally relevant as inﬂammation
is implicated in almost every aspect of chronic tissue diseases [5]. Be-
sides inﬂammation, angiogenesis is believed to play an important role
in tissue remodeling associated with chronic injury. This is exempliﬁed
by the fact that ﬁbroblasts respond to hypoxia with expression of cyto-
kines such as ﬁbroblast growth factor (FGF), vascular endothelial
growth factor (VEGF) and angiopoietinswhich are intrinsically involved
in formation of new blood vessels [6,7].
In recent years, chemokines released by various tissue resident and
inﬁltrating cells, and their cognate receptors have been implicated in
the propagation of virtually all of these biological processes [8]. The cur-
rent review focuses on the role of chemokines and their receptors in
various ﬁbrotic diseases with enhanced ﬁbrosis-associated inﬂamma-
tion and angiogenesis (Fig. 1).
2. Basic aspects of inﬂammation involved in ﬁbrotic processes
Recruitment of inﬂammatory cells is a fundamental process of the
early phases of wound healing. However, certain types of tissue inju-
ry can result in dysregulation of inﬂammatory and wound-healing
response, preceding the formation of ﬁbrosis. Initial inﬂammation
is characterized by the rapid inﬁltration of polymorphonuclear neu-
trophils (PMN) followed by monocytes which differentiate into
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Fig. 1. Key features of tissue ﬁbrosis. Fibrogenesis, characterized by excessive deposition and accumulation of ECM, is a central pathologic process of tissue ﬁbrosis. This process is
initiated by a multitude of chemokines which induce their pleiotropic effect by interacting with their cognate receptors, expressed by various target cells. Injured endothelial cells
induce the release of angiogenic factors such as VEGF, PDGF, bFGF and also chemokines, which in turn alter endothelial permeability and support the recruitment and proliferation
of leukocytes. Under normal conditions, these factors and cell types drive the wound healing process. In ﬁbrosis, repetitive vascular and tissue injury and deregulated inﬂammatory
response as well as endothelium repair induce persistent inﬂammation and angiogenesis. The immunologic response includes the accumulation of macrophages and neutrophils in
affected tissue, which amplify the recruitment and activation of leukocytes. In this context, the predominantly represented subset of T cells TH2 with enhanced pro-ﬁbrogenic cy-
tokine and chemokine release (interleukin-4, interleukin-5, interleukin-13 and CCL2) contribute to the progression of ﬁbrosis by activation of ﬁbroblasts. The angiogenic response
includes the release of angiogenic factors leading to changes in endothelial cell–cell and cell–matrix interactions, including degradation of VBM and activation of endothelial cells,
ﬁnally resulting in new blood vessels. This angiogenic phase is characterized by an imbalance of ELR+/ELR− CXC chemokine presence with a predominance of angiogenic ELR+
chemokines. Endothelial and resident cell-expressed pro-ﬁbrogenic and angiogenic chemokines and growth factors activate resident ﬁbroblasts. Excessive production and deposi-
tion of ECM proteins by these cells results ultimately in permanent scarring. bFGF, basic ﬁbroblast growth factor; IFN, interferon; IL, interleukin; MMP, matrix metalloproteinase;
PDGF, platelet-derived growth factor; TGF-β, transforming growth factor β; TH1, type 1 T helper cells; TH2, type 2 T helper cells; TIMP, tissue inhibitor of metalloproteinases; TREG,
regulatory T cells; VBM, vascular basement membrane; VEGF, vascular endothelial growth factor.
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tute the ﬁrst line of immune defense [9,10]. Upon activation, neutro-
phils and macrophages release a multitude of inﬂammatory and
ﬁbrogenic cytokines [1].
Macrophages are divided into classically (M1) or alternatively
(M2) activated phenotypes dependent on the cytokine environment.
M1-polarized cells are mainly responsive to type 1 inﬂammatory cy-
tokines, while M2 has a restricted expression of alternative markers
[11]. Moreover, M2 macrophages are subdivided in the subsets
M2a, M2b or M2c depending on their molecule-based induction.
Speciﬁcally, M2a are activated by IL-4 and IL-13, M2b by immune
complexes in combination with IL-1β or LPS, and M2c by IL-10,
TGF-β, or glucocorticoids [12]. An increased level of M2macrophages
has been observed in patients with ﬁbrotic diseases [13,14], indicat-
ing that these cells are a potential source of ﬁbrogenic cytokines.
Through chemotaxis T and B leukocytes are also recruited to the
site of inﬂammation and further promote secretion of ﬁbrogenic cy-
tokines (TGF-β1, PDGF, IL-1) [1].T leukocytes are subdivided in CD4+ helper (TH) or CD8+ cytotoxic
cells. CD4+ helper cells are further divided in TH1 or TH2 subsets based
on the phenotype of expressed cytokines [15]. TH1 cells express
interferon-γ (IFN-γ), IL-2 and IL-12, which induce potent anti-ﬁbrotic
activities, while TH2 cells promote B cell-derived humoral immunity
and ﬁbrosis by secreting IL-4, IL-5, IL-10, and IL-13 [16]. In turn,
recruited T cells can activate ﬁbroblasts to produce collagen, ultimately
resulting in tissue scarring.
During the ﬁbrotic process, a complex interaction of cytokines,
chemokines, growth factors, proteases, and ECM proteins, released
by altered mesenchymal cells (ﬁbroblasts and myoﬁbroblasts) and
resident epithelial cells are considered to amplify the inﬂammatory
inﬁltrate.
3. Basic aspects of angiogenesis involved in ﬁbrotic processes
Angiogenesis is a crucial biological process under both physiologic
and pathologic conditions. Pathologic angiogenesis is widely associated
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metabolic demands of the affected tissue are extremely high and re-
quire enormous capillary blood supply. The process of angiogenesis is
divided into two phases, induction and resolution. The inductive
phase involves the release of pro-angiogenic factors such as vascular en-
dothelial growth factor (VEGF), basic ﬁbroblast growth factor (bFGF),
PDGF, TGF-β1 and epidermal growth factor (EGF) by stromal cells, lead-
ing to changes in endothelial cell–cell and cell–matrix interactions, in-
cluding degradation of vascular basement membrane (VBM) and
activation of endothelial cells. The resolution phase comprises the re-
cruitment of perivascular supporting cells, resulting in an assembly of
new fully functional blood vessels. Under normal circumstances, the
microvasculature is maintained in a quiescent state regulated by a ﬁne
tuned balance between various pro- and anti-angiogenic factors [18].
In ﬁbrosis, a dysregulation of this balance with a predominance of in-
herent pro-angiogenic actions has been shown to contribute to the pro-
gression of tissue scarring [9–11]. Besides PDGF and TGF-β, VEGF has
also been identiﬁed to play a potent pro-ﬁbrogenic role during
ﬁbrogenesis [6,19]. Interestingly, hypoxia is one of the most potent
stimuli which can induce the gene expression of VEGF [14], and is there-
fore considered as an important component of homeostatic mecha-
nisms which stimulates angiogenesis and also ﬁbrosis in tissues
[6,20,21]. Furthermore, pericytes and ﬁbroblasts are very sensitive to
hypoxia and play a crucial role in angiogenesis by interacting with en-
dothelial cells through PDGF and VEGF signaling [20].
4. Chemokine system
Chemokines are a family of small heparin-binding chemotactic cyto-
kines, which are long known for orchestrating the recruitment of leuko-
cytes to sites of inﬂammation. Apart from immune cell trafﬁcking,
chemokines alsomodulate a number of other crucial biological process-
es including hematopoiesis, cardiogenesis, vasculogenesis and neuronal
development [8]. Members of the chemokine family share similar struc-
tures and can be divided into four groups, CXC, CC, C and CX3C, charac-
terized by the number of amino acids located between the N-terminal
cysteine residues [22]. They induce their pleiotropic effects by
interactingwith G-protein-coupled receptors (GPCR) expressed on var-
ious target cells (Table 1). The chemokine network, consisting of at least
50 ligands and 19 receptors, is a highly redundant and promiscuous sys-
tem [23,24]. Moreover, the ability of chemokines to form multimeric
and heterodimeric structures further contributes to the biological
complexity of chemokine functions. According to these observations,Table 1
Chemokine receptors and ligands in ﬁbrosis.
Chemokine
receptor
Chemokine ligand Cell expression
CC family
CCR1 CCL3, CCL5, CCL7, CCL14 Fibroblast, monocyte,
NK cell, platelet, TH1 cell
CCR2 CCL2, CCL7, CCL8, CCL13, CCL16 Fibroblast, dendritic cell,
monocyte, TH1 cell
CCR3 CCL5, CCL7, CCL8, CCL11, CCL13 Basophil, eosinophil, platelet,
TH2 cell
CCR4 CCL17, CCL22 Endothelial cell, NK
cell, platelet, TH2 cell
CCR5 CCL3, CCL4, CCL5, CCL11, CCL14,
CCL16
Fibroblast, macrophage,
monocyte, T cell, TH1 cell
CCR6 CCL20 B cell, dendritic cell, T cell
CCR7 CCL19, CCL21 Dendritic cell, T cell
CXC family
CXCR3 CXCL4, CXCL9, CXCL10, CXCL11 Endothelial cell, NK cell, TH1
cells, TREG cell
CXCR4 CXCL12 Fibroblast, endothelial cell,
plateletvarious approaches have been studied to dissect distinct roles of
chemokines in different diseases. Speciﬁcally, the use of knockout and
transgene technologies in vivohas offered new avenues to decipher var-
ious functional aspects of chemokines in diverse disease models [25].
5. Liver ﬁbrosis
Liver ﬁbrosis is characterized by hepatocellular necrosis, inﬂam-
mation, tissue remodeling and angiogenesis ultimately resulting in
cirrhosis or hepatocellular carcinoma [19,26,27]. The recruitment of
leukocytes into the injured liver is one of the main features orches-
trated by chemokines during hepatic ﬁbrogenesis. Overall, a large
number of chemokines is expressed by hepatic resident cells which
directly drive the inﬂux of speciﬁc immune cells during injury
[28,29]. Among hepatic resident cells, hepatic stellate cells (HSCs)
play a pivotal role in the initiation and progression of liver ﬁbrosis
by secreting large amounts of extracellularmatrix proteins [26]. Stellate
cells are also able to express a multitude of chemokines, including the
CC chemokines CCL2, CCL3, CCL5, as well as the CXC chemokines
CXCL8, CXCL9, CXCL10 [30] and CXCL12 [31]. Interestingly, the CXC
family of chemokines also operate in pathological angiogenesis preced-
ing/perpetuating ﬁbrosis. CXC chemokines containing the ELR motif
(ELR+) induce angiogenesis, while chemokines lacking this motif
(ELR−) suppress the formation of new blood vessels [7,32]. Many of
these chemokines have already been functionally linked to liver ﬁbrosis
in murine models and in patients with chronic (mainly viral induced)
liver diseases.
5.1. The role of CC chemokines in liver ﬁbrosis
Awell described chemokine pathway in ﬁbrotic liver diseases impli-
cates the chemokine receptors CCR1 and CCR5. CCR1 shares the ligands
CCL3 and CCL5 with CCR5. Genetic deﬁciency of any of these receptors
leads to attenuation of experimental liver ﬁbrosis inmice [33], function-
ally validating genetic studies showing reduced liver scarring in hepati-
tis C virus (HCV) infected individuals possessing a 32 base pair deletion
in CCR5 (CCR5Δ32) [33,34]. Interestingly, there is growing evidence for
the functional divergence of these receptors in the liver. While CCR1 in-
duces its pro-ﬁbrotic effects through hematopoietic cells, CCR5 appears
to contribute to liver ﬁbrosis through resident liver cells [33]. Their
shared ligands CCL3 (own unpublished data) and CCL5 [35], seem to
be central regulators of this pathway, as mice lacking either of these
chemokines also exhibited reduced experimental hepatic ﬁbrosis asso-
ciated with decreased stellate cell activation and immune cell inﬁltra-
tion. Importantly, antagonism of CCR1 and CCR5 with Met-CCL5
attenuated liver ﬁbrosis and expedited the regression of ﬁbrosis upon
cessation of injury [35]. Also, the inhibition of oligomerization and gly-
cosaminoglycan binding of CCL5 by (44)AANA(47)-CCL5, a mutated
CCL5 protein, ameliorated experimental liver ﬁbrosis in vivo [36].
The chemokine CCL2, also known as MCP-1, is the ﬁrst chemokine
which has been directly implicated in hepatic ﬁbrogenesis [37]. In pa-
tients with chronic hepatitis, CCL2 expression by liver resident cells is
increased within the liver [38]. CCL2 interacts with the chemokine re-
ceptor CCR2 which is also the prominent receptor for three other CC
chemokines, CCL8 (MCP-2), CCL7 (MCP-3) and CCL13 (MCP-4). This re-
ceptor is present on different cells including memory TH1 cells [39],
dendritic cells [40], CD14++ CD16− monocytes [41] as well as on he-
patic stellate cells [42]. CCR2 deﬁcientmicewere protected from liver ﬁ-
brosis in two independent injury models [33,43] associated with a
reduced inﬁltration of CCR2 expressing inﬂammatory macrophages.
Moreover, CCR2 deﬁciency also ameliorated direct pro-ﬁbrotic effects
on HSCs [42]. Similarly to CCR2, the lack of another CC chemokine re-
ceptor CCR8 ameliorated experimental liverﬁbrosis in two independent
injury models due to reduced CCL1-directedmigration of inﬂammatory
macrophages into the liver [44]. Taken together, these data reveal a
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liver.5.2. The role of CXC chemokines in liver ﬁbrosis
In liverﬁbrosis, a predominant CXC chemokine receptor,which is in-
volved in the positioning of T-helper (TH) 1 and T-regulatory (TREG)
cells into the liver, is CXCR3 [45]. This receptor and its splice variant
bind the interferon-γ-inducible chemokines CXCL9, CXCL10, CXCL11,
and CXCL4 in humans [46]. Interestingly, TH1 cells expressing IFN-γ
and IL-12 have been shown to inhibit the development of ﬁbrosis,
while TH2 cells producing IL-4 and IL-13 have been found to exacerbate
experimental liver ﬁbrosis [16,47,48]. CXCR3 and CCR5 are preferen-
tially expressed on TH1 cells, whereas CCR3 and CCR4 are expressed
on TH2 cells [49]. Mice lacking CXCR3 are more prone to liver ﬁbrosis
which is initiated by the loss of anti-ﬁbrogenic and angiostatic effects
of CXCL9 on hepatic stellate cells [50] and sinusoidal endothelial cells
[51], supporting the hypothesis that angiogenesis promotes the ﬁ-
brotic process [6]. In contrast, the deletion of the other CXCR3 ligand
CXCL10 inhibits experimental liver ﬁbrosis [52]. These results are in
line with clinical studies showing a high serum and intrahepatic ex-
pression of CXCL10 in severe HCV induced ﬁbrosis [50,53]. CXCL10
appears to be also involved in early ﬁbrosis recurrence after liver
transplantation for hepatitis C [54]. The paradox that cytotoxic
CXCR3+ TH1 cells attracted by CXCL10 fail to clear the hepatitis C
virus might be explained by data obtained by Casrouge and col-
leagues. They showed that the main part of CXCL10 in the serum of
patients is cleaved by dipeptidyl peptidase IV (DPP4). The resulting
truncated form indeed antagonizes the CXCR3 pathway leading to
suppressed recruitment of CXCR3+ T cells into the infected livers [55].
In humans, the platelet-derived chemokine CXCL4 is a further ligand
of CXCR3. In linewith data obtained with CXCL10 knockoutmice, CXCL4
deﬁcient mice were protected from experimental liver ﬁbrosis due to
impeded migration of CD8+ T cells and reduced CXCL4 induced
pro-inﬂammatory chemokines, such as CXCL1 and CCL5, within the
liver [56]. Moreover, dimerization of CXCL4 with CCL5 may induce en-
hanced CCL5 driven vascular monocyte accumulation [57].5.3. The role of CX3C chemokines in liver ﬁbrosis
An anti-ﬁbrotic role of monocyte-associated chemokine receptor 1
CX3CR1, the only receptor of the CX3C class of chemokines, and its li-
gand CX3CL1 in liver ﬁbrosis was shown by Karlmark et al. Accordingly,
CX3CR1 protected against liver ﬁbrosis by regulating differentiation and
survival of liver monocytes [58], suggesting that pharmacological mod-
ulation of this pathway may offer new therapeutic strategies.6. Pulmonary ﬁbrosis
The pathophysiology of pulmonary ﬁbrosis is a complex biological
process which includes features of abnormal inﬂammatory wound
healing, the deposition of extracellularmatrix proteins and exaggerated
angiogenesis [7]. At advanced stages, scarring of the lung can lead to
pulmonary hypertension and respiratory failure which is associated
with strongly increased morbidity and mortality in affected patients
[59]. Fibroblasts, myoﬁbroblasts and ﬁbrocytes are the main sources of
a steady accumulation of the scar tissue [60,61]. These cell types modu-
late the derangement of alveolar structures and loss of elasticity [60,61].
Pulmonary ﬁbrotic diseases are often associated with arrest of mono-
cytes, neutrophils, mast cells and other leukocytes [59]. The release of
CC and CXC chemokines by these pro-inﬂammatory cells and also by
resident cells (alveolar epithelial cells) enhance the inﬂammatory and
ﬁbrotic effects in the lung [62,63].6.1. The role of CC chemokines in pulmonary ﬁbrosis
In murine models, CCL2 and its cognate receptor CCR2 has been
implicated in the pathogenesis of pulmonary ﬁbrotic diseases [64].
Besides its speciﬁc role as chemoattractant for monocytes, CCL2 me-
diates direct pro-ﬁbrogenic effects by signaling ﬁbroblasts to express
TGF-β, a known collagen production stimulator [65]. CCR2 is present
on monocytes, activated T cells, B cells, NK cells, ﬁbroblasts and mast
cells within the lung [66]. Mice lacking CCR2 develop less severe pul-
monary ﬁbrosis in different experimental ﬁbrosis models compared
to control mice [67]. In this context, CCL2 signal transduction via its
cognate receptor CCR2 played an important role in cellular activation
rather than immune cell trafﬁcking into the lung [67]. These ﬁndings
were further supported by studies of Okuma et al. showing an atten-
uation of pulmonary ﬁbrosis in CCR2 deﬁcient mice due to reduced
macrophage mediated MMP-2 and MMP-9 production [68]. These
results are in line with human studies showing a high mRNA and
protein expression of CCL2 in lung epithelial cells from patients
with idiopathic pulmonary ﬁbrosis. Moreover, analysis of bronchoal-
veolar lavage ﬂuid from patients with idiopathic pulmonary ﬁbrosis
showed enhanced levels of CCL2, CCL3, and CCL4, while CCR5 expres-
sion was signiﬁcantly reduced [69]. CCR5, expressed on activated T
cells and alveolar macrophages, interacted with the ligands CCL3
and CCL5 [69,70]. The reduction of this receptor, which is preferen-
tially expressed on TH1 cells, was associated with an increase of
IL-4 and a decrease of IFN-γ release in patients with advanced stages
of pulmonary ﬁbrosis [69]. Interestingly, IFN-γ is a TH1 cytokine
which suppresses collagen synthesis by ﬁbroblasts, whereas IL-4 is a
TH2 cytokinewhich stimulatesﬁbroblast proliferation and collagen syn-
thesis. These ﬁndings support the hypothesis of an important role of the
TH1/TH2 balance for the progression of pulmonary ﬁbrosis, as it has
been described for liver ﬁbrosis [39,69]. In contrast to this hypothesis,
CCR5−/− mice have been shown to be less prone to experimental pul-
monary ﬁbrosis compared to wild-type mice [71]. Similarly to CCR5,
the CC chemokine receptor CCR1 has also been shown to play an impor-
tant role in experimental pulmonary ﬁbrosis. Upon injury, CCR1mRNA
expression peaked at day 7, reﬂected by augmented expression of its li-
gands CCL3 and CCL5. Functionally, blockade of CCR1 led to reduced ex-
perimental ﬁbrosis associated with decreased immune cell inﬁltration
into the lung [72]. Another important CC chemokine involved in ﬁbrosis
of the lung is the eosinophil chemotactic factor CCL11 (eotaxin-1). It
binds to its cognate receptor CCR3, which is highly expressed by eosin-
ophils as well as other immune cells [73,74]. In murine lung ﬁbrosis
models, the expression of CCL11 and CCR3 was increased within the
lung and was associated with progressive pulmonary inﬁltration of eo-
sinophilic and neutrophilic granulocytes [73].
6.2. The role of CXC chemokines in pulmonary ﬁbrosis
CXC chemokines and receptors also operate in pulmonary ﬁbrosis
[75]. CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 act primarily
on T helper 1 (TH1) and natural killer T (NKT) cells [75]. Like in the
liver, evidence frommouse and human studies implicates TH1 response
as an anti-ﬁbrogenic and TH2 response as a pro-ﬁbrogenic event during
pulmonary ﬁbrogenesis [16,76]. Previous studies have suggested that
CXCR3+ cells potentiate TH1 responses [16]. Inmousemodel, CXCR3 de-
ﬁcient mice indeed showed pronounced experimental pulmonary ﬁ-
brosis with decreased expression levels of IFN-γ and a reduction of
IFN-γ positive T cells [77], suggesting CXCR3 as a non-redundant recep-
tor limiting lung ﬁbrosis. Notably, such a TH2 dominant environment
has also been associated with severe liver and renal ﬁbrosis in CXCR3
deﬁcient mice [50,78]. Interestingly, all ligands of CXCR3, which lack
the ELR motif (ELR−), also have angiostatic actions, whereas ELR+
CXC chemokines CXCL2, CXCL5 and CXCL12 promotes angiogenesis in
patients with idiopathic pulmonary ﬁbrosis (IPF) [79–81]. This seems
especially relevant as pulmonary angiogenesis has been strongly linked
1045H. Sahin, H.E. Wasmuth / Biochimica et Biophysica Acta 1832 (2013) 1041–1048to progressive ﬁbrogenesis [82]. An imbalance of ELR+/ELR− CXC che-
mokine presence with a predominance of angiogenic ELR+ chemokines
has been shown to contribute to the pathogenesis of IPF [79–81]. Func-
tionally, blocking of CXCL2 [81] or systemic administration of CXCL10 or
CXCL11 led to a strong attenuation of experimental pulmonary ﬁbrosis
via reduction of angiogenesis within the lung [83–85]. Moreover, re-
combinant murine IL-12 also reduced pulmonary ﬁbrosis triggered by
IFN-γ [86]. These ﬁndings identify IFN-γ and the CXCR3 ligands
CXCL10 and CXCL11 as inhibitors of pulmonary ﬁbrosis.
7. Renal ﬁbrosis
Renal ﬁbrosis is characterized by glomerulosclerosis and destructive
interstitialﬁbrosis, and is closely correlated to loss of renal function. The
ﬁbrotic process is initiated by cellular activation of resident cells (tubu-
lar epithelial cells, vascular endothelial cells and ﬁbroblasts) and by re-
cruitment of activated leukocytes (e.g. macrophages) followed by an
excessive expansion of interstitial matrix components by activated
renal ﬁbroblasts. Within the last years, a critical role of various
chemokines and their receptors has been identiﬁed in these biological
processes.
7.1. The role of CC chemokines in renal ﬁbrosis
Recent studies better deﬁned functions of the chemokine CCL2 as a
mediator of experimental renal ﬁbrosis. In various rodent models of
renal ﬁbrosis, CCL2 expression was increased by tubular epithelial
cells associatedwith enhancedmacrophage inﬁltration [87]. Theseﬁnd-
ings are congruent with human data showing an increased expression
of CCL2 and macrophage inﬁltration in kidney of patients with diabetic
nephropathy [88,89]. The functional aspect of CCL2 in interstitial ﬁbro-
siswas conﬁrmed by various animal studies using neutralizing antibody
or CCL2 deﬁcient mice. Importantly, neutralization of CCL2 reduced in-
terstitial leukocyte and collagen accumulation in mice with crescentic
nephritis [90]. In accordance with these ﬁndings, mice lacking the
CCL2 gene develop less severe experimental tubulointerstitial ﬁbrosis
[91]. Also, the blockade of its receptor CCR2 is associated with reduced
interstitial ﬁbrosis after unilateral ureter ligation (UUO) [92]. These
ﬁndings were further reﬂected by attenuated interstitial leukocyte
and ﬁbroblast accumulation. In a spontaneous mouse model of lupus
nephritis, MRL/MpJ Faslpr/lpr (MRL/lpr) mice showed a higher expres-
sion of chemokines associatedwith enhancedmononuclear cell inﬁltra-
tion and expression of chemokine receptors CCR1, CCR2, and CCR5 [93].
In this ‘real-life’model, genetic deletion of CCL2 (MRL/lpr/CCL2−/−) led
to reduced macrophage and T cell inﬂux, proteinuria and also renal
damage [94], identifying the CCL2–CCR2 axis as a potential target for
therapeutical strategies for certain types of nephritis.
These ﬁndings are further supported by human studies in patients
with lupus nephritis showing a correlation between urinary CCL2 levels
and severity of renal disease as well as macrophage inﬁltration [95].
Moreover, glucocorticoid treatment of the lupus nephritis led to an at-
tenuation of urinary CCL2 levels conﬁrming in vitro results which
showed an inhibitory effect of glucocorticoids on CCL2 expression in
renal cells [96].
Other CC chemokine receptors involved in chronic renal ﬁbrotic dis-
eases are CCR1 and CCR5. In experimental interstitial ﬁbrosis, their com-
mon ligand CCL5 was predominantly expressed by leukocytes and also
by interstitial ﬁbroblasts in vivo [87,93]. Along this chemotactic gradient,
CCR5+ leukocytes migrated to the interstitium and the number of
CCR5+ leukocytes within the interstitium correlated with serum cre-
atinine levels in human biopsies of various renal diseases [97]. How-
ever, in contrast to liver [33] and lung [71] ﬁbrotic disease models,
the deletion of CCR5 in the lupus nephritis model (MRL/lpr/
CCR5−/−) led to an unexpected deterioration of kidney damage and
was associated with an increase in mononuclear cell inﬁltration but
a decrease in renal T cell accumulation [98]. This apparentlyprotective role of CCR5 has been explained by a negative feedback
loop of its own ligands leading to reduced inﬂammatory cell inﬂux
[98]. On the other hand, the antagonism of CCR5 with Met-CCL5 for
seven days after renal transplantation in rats ameliorated chronic al-
lograft nephropathy with reduced proteinuria, glomerulosclerosis
and interstitial ﬁbrosis after 28 weeks, indicating the importance of
CCR5 pathway for the alloimmune response [99]. These results are
in line with earlier clinical studies showing improved graft survival
in homozygous CCR5Δ32 individuals compared to either heterozy-
gote or wild-type CCR5 renal transplant recipients [100]. Important-
ly, the blockade of the other CCL5 receptor CCR1 also showed
beneﬁcial effects on the progression of chronic renal allograft dam-
age [101].
Taken together, these in vivo and ex vivo analysis of CC chemokines
and their receptors provided further valuable insights into immune
cell mediated progressive tubulointerstitial damage and ﬁbrosis. Thus,
antagonism of these proteins may represent a therapeutic option for
chronic renal inﬂammation and ﬁbrosis.
7.2. The role of CXC chemokines in renal ﬁbrosis
CXCR3 and its ligand CXCL10 has also been involved in renal ﬁbrotic
disorders. The antagonism of the CXCL10–CXCR3 axis by neutralizing
antibody promoted renal ﬁbrosis triggered by altered balance of hepa-
tocyte growth factor (HGF) and TGF-β1 activity. Interestingly, CXCL10
inhibition affected neither macrophage nor T cell inﬂux into the kidney
[78]. These ﬁndings identify the CXCL10–CXCR3 axis as an important
potential target for therapeutical strategies in progressive renal ﬁbrosis.
8. Dermal ﬁbrosis—scleroderma
Scleroderma, also known as systemic sclerosis (SSc), is characterized
by three distinct pathologic processes: autoimmune inﬂammation, ﬁ-
brosis and angiogenesis. Accordingly, the interplay of leukocytes, endo-
thelial cells and ﬁbroblasts seems to play a central role in the
pathogenesis of scleroderma. Chemokines have indeed been recognized
as crucialmediators of leukocyte trafﬁcking into the sclerotic skin [102].
Apart from inﬂammation, chemokines are also involved in other patho-
logic processes including angiogenesis, ﬁbrogenesis and cell differentia-
tion which contribute to clinical manifestation of SSc.
8.1. The role of CC chemokines in skin ﬁbrosis
Among chemokines, CCL2 has been identiﬁed as the most critical
chemokine for tissue ﬁbrosis and inﬂammation in systemic sclerosis
(SSc). In patients with SSc, CCL2 levels are increased in serum, along
with enhanced CCL2 expression in the epidermis, inﬂammatory mono-
nuclear cells, and endothelial cells [103]. These ﬁndings are in line with
in vitro experiments demonstrating a transendothelial leukocytemigra-
tion mediated by SSc ﬁbroblast-released biologically active CCL2 [104].
The functional relevance of CCL2 in tissue ﬁbrosis was further validated
by animal models. In a murine sclerodermatous graft-versus-host dis-
ease (GVHD) model, CCL2 has been found to precede the progression
of skin and pulmonary ﬁbrosis [105]. Functionally, the lack [106] or neu-
tralization [107] of CCL2 ameliorated experimental dermal sclerosis in
vivo associated with a decrease of inﬂammatory cells and collagen con-
tent in the skin. Furthermore, pharmacological antagonism of CCL2 and
CCL4 with SKL-2841 protected bleomycin-induced dermal ﬁbrosis
[108]. These results provide evidence that CCL2 plays a critical role in
positioning of leukocytes into the skin in early stages of SSc, which in
turn activate resident ﬁbroblasts to produce collagen, ultimately
resulting in tissue scarring. The expression of another CC chemokine,
CCL5, has also been functionally involved in SSc. In patients with SSc,
mRNA and protein levels of CCL5 were increased in bronchoalveolar la-
vage ﬂuid [109] and also within the skin [110,111]. In a murine
sclerodermatous graft-versus-host disease (GVHD) model, cutaneous
Table 2
Pro- and anti-ﬁbrotic chemokines involved in ﬁbrotic diseases affecting the liver, lung,
kidney and skin.
Chemokine Liver Lung Kidney Skin
Pro-ﬁbrogenic CCL1, CCL2,
CCL3, CCL5,
CXCL1, CXCL4,
CXCL10
CCL2, CCL3,
CCL5, CCL11,
CXCL2, CXCL5,
CXCL12
CCL2,
CCL5
CCL2, CCL3, CCL5,
CCL7, CCL17, CCL22,
CCL27, CXCL1, CXCL8,
CXCL16
Anti-ﬁbrogenic CXCL9, CX3CL1 CXCL10,
CXCL11
CXCL10 CXCL9, CXCL10,
CXCL11, CXCL12
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cently, signiﬁcant abnormalities of CCL7 expression have also been
shown in SSc. Notably, abundant CCL7 levels in serum of patients with
SSc correlated with the extent of skin sclerosis and the severity of pul-
monary ﬁbrosis [112]. In line with these human data, CCL7 expression
was increased in type 1 tight-skin mice, which spontaneously develop
skin ﬁbrosis [113], deﬁning CCL7 as a potential mediator of dermal ﬁ-
brosis in SSc. Increased TH2 chemokines, CCL17, CCL22 [114] and
CCL27 [115], in serum of patients with SSc has also been linked to the
extent of skin sclerosis.
8.2. The role of CXC chemokines in dermal ﬁbrosis
CXC chemokines with ELR motif attract neutrophils and mediate
pro-angiogenic effects. The ELR+ chemokines involved in SSc are
CXCL1, CXCL8 and CXCL16. Increased serum CXCL1 and CXCL8 levels
have been shown in patients with SSc [116]. Moreover, there is growing
evidence of genetic association between the CXCL8 gene polymorphism
and increased risk of SSc [117]. The other angiogenic CXC chemokine
CXCL16 and its receptor CXCR6 were also elevated in SSc serum and
on SSc dermal endothelial cells, respectively [118]. CXC chemokines
without ELR motif orchestrate CXCR3+ TH1 cells and mediate
angiostatic effects. These ELR− CXC chemokines involved in SSc are
CXCL9, CXCL10, CXCL11 and CXCL12. Angiostatic CXCL9 and CXCL10
were increased in serum and highly expressed in skin of SSc patients
compared to controls [114,118]. In contrast, the mRNA and protein ex-
pression of their receptor CXCR3 was decreased in SSc patients,
suggesting a CXC chemokine receptor-regulated angiogenic activity in
SSc skin.
9. Chemokine receptor antagonistic strategies in human
ﬁbrotic diseases
The growing evidence that chemokines and their receptors are in-
volved in tissue ﬁbrosis [33,35], might lead to treatment of patients
with ﬁbrotic diseases with chemokine receptor antagonists. Indeed,
the CCR5 receptor antagonist maraviroc is under investigation as a tar-
get of anti-ﬁbrotic therapies in HCV/HIV co-infected subjects (www.
clinicaltrials.gov). Other chemokine receptor antagonists are also ac-
tively investigated in early human trials. These include the CC receptor
1 antagonist BAY86-5047 in patients with endometriosis and the CCR2
antagonist MLN1202 in subjects with a risk for cardiovascular diseases
(www.clinicaltrials.gov). However, it should always be considered
that many chemokine receptor antagonists failed to show efﬁcacy in
clinical trials, despite data of successful therapeutical interventions in
murinemodels [119]. Reasons for these negative results might be phar-
macokinetic aspects of the drugs, off-target effects and cytotoxicity at
increased doses. While these features are applicable to all G-protein-
coupled receptors, more unique/speciﬁc to the chemokine system is
its high degree of redundancy and complexity [120]. Nevertheless, al-
though there is a large empirical gap in our knowledge of the chemo-
kine system, the use of chemokine receptor antagonist is considered
as a great therapeutic potential for ﬁbrogenic diseases in the future.
10. Conclusions
Tissue ﬁbrosis is a dynamic progression of aberrant wound healing
which is accompanied by chronic inﬂammation and angiogenesis. This
ﬁbrotic process represents a risk for morbidity andmortality associated
with organ failure in various ﬁbrotic diseases affecting the liver, lung,
kidney and skin. The trafﬁcking, activation and proliferation of in-
ﬂammatory cells and their interaction with resident cells are orches-
trated by chemokines and their cognate receptors. Importantly,
some chemokines such as CCL2, CCL3 and CCL5 have shown common
effects across different diseases, while others such as CXCL10 medi-
ate tissue speciﬁc effects (Table 2). This fact needs to be taken intoaccount when translating pre-clinical animal data to human clinical
trials. Nevertheless, given the complexity and redundancy of the
chemokine network, further investigations of chemokine effects in
tissue ﬁbrosis are warranted as the search for novel targets for spe-
ciﬁc ﬁbrotic therapeutic agents is ongoing.Conﬂict of interest statement
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